A new class of anti-HIV-1 agents targeted toward the nucleocapsid protein NCp7: The 2,2′-dithiobisbenzamides
John M. Domagala(Pfizer (United States)), Robert Schultz(Sarepta Therapeutics (United States)), William G. Rice(Frederick National Laboratory for Cancer Research), Jeffrey D. Scholten(Io Therapeutics (United States)), Patricia J. Harvey(University of Greenwich), Peter J. Tummino(Intarcia Therapeutics (United States)), Yuntao Song(Chinese Academy of Sciences), Rocco D. Gogliotti(Vanderbilt University), Donald Hupe(Pfizer (United States)), Joseph P. Sanchez(University of Michigan), J. V. N. Vara Prasad(Pfizer (United States)), Michael A. Stier(Io Therapeutics (United States)), Tod P. Holler(Pfizer (United States)), John P. Bader(Sarepta Therapeutics (United States)), Steve Gracheck(Io Therapeutics (United States))
Cited by 42
Related Papers
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
|Biochemistry|2008|550